|
20 Sep 2020 |
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
|
|
20 Sep 2020 |
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
|
|
20 Sep 2020 |
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
|
|
20 Sep 2020 |
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer
|
|
20 Sep 2020 |
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
|
|
20 Sep 2020 |
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
|
|
20 Sep 2020 |
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
|
|
18 Sep 2020 |
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
|
|
18 Sep 2020 |
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
|
|
18 Sep 2020 |
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
|
|
18 Sep 2020 |
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020
|
|
18 Sep 2020 |
Celltrion receives Korean MFDS approval to initiate Phase II/III pivotal trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59
|
|
18 Sep 2020 |
Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
|
|
18 Sep 2020 |
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
|
|
18 Sep 2020 |
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
|
|
18 Sep 2020 |
ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks
|
|
18 Sep 2020 |
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
|
|
18 Sep 2020 |
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
|
|
17 Sep 2020 |
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
|
|
17 Sep 2020 |
Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia
|
|
17 Sep 2020 |
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
|
|
16 Sep 2020 |
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
|
|
16 Sep 2020 |
EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor
|
|
16 Sep 2020 |
Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
|
|
16 Sep 2020 |
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML
|
